These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34182528)

  • 21. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
    Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting oncotype DX recurrence scores using locally available immunohistochemical markers: experience in a district general hospital.
    Humphris K; Stephenson J; Kumaraswamy V
    J Clin Pathol; 2023 Apr; 76(4):252-255. PubMed ID: 34903609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.
    Tan AC; Li BT; Nahar K; Danieletto S; Fong ES; Currer T; Parasyn A; Middleton P; Wong H; Smart D; Rutovitz JJ; McCloud P; Hughes TM; Marx GM
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e161-e166. PubMed ID: 28960862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.
    Yoo SH; Kim TY; Kim M; Lee KH; Lee E; Lee HB; Moon HG; Han W; Noh DY; Han SW; Kim TY; Im SA
    Clin Breast Cancer; 2020 Apr; 20(2):98-107.e1. PubMed ID: 31522959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay.
    Lin HK; Can T; Kahn A; Flannery CA; Hoag J; Akkunuri A; Bailey H; Baehner R; Pusztai L; Rozenblit M
    Oncologist; 2023 Oct; 28(10):e973-e976. PubMed ID: 37656608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score.
    Wilson PC; Chagpar AB; Cicek AF; Bossuyt V; Buza N; Mougalian S; Killelea BK; Patel N; Harigopal M
    Breast J; 2018 Nov; 24(6):976-980. PubMed ID: 30230117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation Between Oncotype Dx Recurrence Score and PREDICT Estimates in Early Breast Cancer: A Single Institution Experience.
    Ibrahim EM; Al-Quzi BA; Shaheen AY; Kulak MH; Refae AA; Al-Foheidi ME
    JCO Glob Oncol; 2024 Aug; 10():e2400112. PubMed ID: 39159413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer.
    Yang PS; Lee YH; Chung CF; Chang YC; Wang MY; Lo C; Tsai LW; Shih KH; Lei J; Yu BL; Cheng SH; Huang CS
    Jpn J Clin Oncol; 2019 Dec; 49(11):1029-1036. PubMed ID: 31287883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
    Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
    J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
    Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
    Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Oncotype DX
    Pardo JA; Fan B; Mele A; Serres S; Valero MG; Emhoff I; Alapati A; James TA
    Ann Surg Oncol; 2021 Mar; 28(3):1320-1325. PubMed ID: 33393046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
    van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
    Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.
    Marazzi F; Barone R; Masiello V; Magri V; Mulè A; Santoro A; Cacciatori F; Boldrini L; Franceschini G; Moschella F; Naso G; Tomao S; Gambacorta MA; Mantini G; Masetti R; Smaniotto D; Valentini V
    Clin Breast Cancer; 2020 Oct; 20(5):e600-e611. PubMed ID: 32565110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
    Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
    Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of Oncotype DX and TAILORx risk categories using histopathological and immunohistochemical markers by classification and regression tree (CART) analysis.
    Ingoldsby H; Webber M; Wall D; Scarrott C; Newell J; Callagy G
    Breast; 2013 Oct; 22(5):879-86. PubMed ID: 23643806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test.
    Dvorak L; Dolan M; Fink J; Varghese L; Henriksen J; Gulbahce HE
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):196-9. PubMed ID: 22914611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.
    Varga Z; Sinn P; Fritzsche F; von Hochstetter A; Noske A; Schraml P; Tausch C; Trojan A; Moch H
    PLoS One; 2013; 8(3):e58483. PubMed ID: 23505515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.